Journal article
Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
- Abstract:
-
Background
Mepolizumab significantly reduces exacerbations in patients with severe eosinophilic asthma. The early identification of patients likely to receive long-term benefit from treatment could ensure effective resource allocation.
Objective
To assess potential continuation rules for mepolizumab in addition to initiation criteria defined as 2 or more exacerbations in the previous year and blood eosinophil counts of 150 cells/mL or more at initiation or 300 cel...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
GlaxoSmithKline
More from this funder
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Journal of Allergy and Clinical Immunology: In Practice Journal website
- Volume:
- 6
- Issue:
- 3
- Pages:
- 874-882.e4
- Publication date:
- 2017-12-01
- Acceptance date:
- 2017-11-15
- DOI:
- EISSN:
-
2213-2201
- ISSN:
-
2213-2198
- Pmid:
-
29258789
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:813157
- UUID:
-
uuid:388560b5-4a45-4839-a9af-d13d8dcfb55f
- Local pid:
- pubs:813157
- Source identifiers:
-
813157
- Deposit date:
- 2018-03-02
Terms of use
- Copyright holder:
- Pavord et al
- Copyright date:
- 2017
- Notes:
- © 2017 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma and Immunology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record